Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001909759 | SCV002186900 | pathogenic | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2021-05-19 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with CACNA1S-related conditions. This variant is present in population databases (rs775883314, ExAC 0.01%). This sequence change creates a premature translational stop signal (p.Val1621Argfs*12) in the CACNA1S gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CACNA1S are known to be pathogenic (PMID: 26247046, 28012042). |
Revvity Omics, |
RCV003487285 | SCV003828843 | uncertain significance | not provided | 2021-10-29 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV004010845 | SCV004815887 | uncertain significance | Malignant hyperthermia, susceptibility to, 5 | 2023-02-24 | criteria provided, single submitter | clinical testing | This pathogenicity assessment is for autosomal dominant malignant hyperthermia susceptibility phenotype. This frameshift variant is predicted to result in an absent or nonfunctional CACNA1S protein product. Loss of CACNA1S gene function due to truncation and splice variants is thought to cause congenital myopathy and hypokalemic periodic paralysis (PMID: 28012042, 34608571, 34777470). However, the role of such loss-of-function variants in autosomal dominant malignant hyperthermia susceptibility is not clearly understood. Therefore, this variant is classified as a Variant of Uncertain Significance. |